Suppr超能文献

位于人视网膜母细胞瘤细胞系中的神经激肽-1受体:其拮抗剂L-732,138的抗肿瘤作用。

Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138.

作者信息

Muñoz Miguel, Rosso Marisa, Coveñas Rafael, Montero Ignacio, González-Moles Miguel Angel, Robles María José

机构信息

Pediatric Intensive Care Unit, Virgen del Rocío University Children's Hospital, Sevilla, Spain.

出版信息

Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2775-81. doi: 10.1167/iovs.05-1591.

Abstract

PURPOSE

The authors have recently demonstrated that substance P and L-733,060 induce cell proliferation and cell inhibition, respectively, in human retinoblastoma cell lines. However, the presence of neurokinin-1 receptors has not been demonstrated in such cell lines, nor is it known whether other neurokinin-1 receptor antagonists exert antitumoral action against retinoblastoma cell lines. The purpose of this study was to demonstrate the presence of neurokinin-1 receptors in the human retinoblastoma cell lines WERI-Rb-1 and Y-79 and to study the growth inhibitory capacity of the neurokinin-1 receptor antagonist L-732,138 against those cell lines. The authors also sought to demonstrate that the administration of L-732,138 or L-733,060 induces apoptosis in retinoblastoma cells and that neurokinin-1 receptors and substance P are present in primary retinoblastoma.

METHODS

Immunoblot analysis was used to determine neurokinin-1 receptors, and a Coulter counter was used to determine viable cell numbers; this was followed by application of the tetrazolium compound WST-8, a colorimetric method, to evaluate cell viability. DAPI stain was applied to assess chromatin condensation, characteristic of apoptosis, and immunoperoxidase was used to demonstrate neurokinin-1 receptors and substance P in eyes with primary retinoblastoma.

RESULTS

Neurokinin-1 receptors were present in both retinoblastoma cell lines studied. Three identical bands (isoforms of approximately 33, 58, and 75 kDa) were observed in both cell lines. Moreover, L-732,138 inhibited the growth of both cell lines studied, with and without previous administration of substance P. This inhibition occurred in a dose-dependent manner, with the IC50 values of 60.47 microM for WERI-Rb1 and 56.78 microM for Y-79. Moreover, apoptosis was observed in both cell lines after the administration of L-732,138 or L-733,060. In fixed eyes with primary retinoblastoma, a high density of neurokinin-1 receptors was observed in tumor cells, whereas a very low number of such cells contained substance P.

CONCLUSIONS

This study showed that the same isoforms of the neurokinin-1 receptor are present in human retinoblastoma cell lines WERI-Rb-1 and Y-79. Both L-732,138 and L-733,060 can induce apoptosis in these cell lines and therefore can act as antitumoral agents. Primary retinoblastoma specimens display neurokinin-1 receptor immunolabeling. These results suggest that the neurokinin-1 receptor may be a promising new target for the treatment of retinoblastoma.

摘要

目的

作者最近证明,P物质和L-733,060分别在人视网膜母细胞瘤细胞系中诱导细胞增殖和细胞抑制。然而,尚未在这类细胞系中证实神经激肽-1受体的存在,也不清楚其他神经激肽-1受体拮抗剂是否对视网膜母细胞瘤细胞系具有抗肿瘤作用。本研究的目的是证实人视网膜母细胞瘤细胞系WERI-Rb-1和Y-79中神经激肽-1受体的存在,并研究神经激肽-1受体拮抗剂L-732,138对这些细胞系的生长抑制能力。作者还试图证明给予L-732,138或L-733,060可诱导视网膜母细胞瘤细胞凋亡,并且神经激肽-1受体和P物质存在于原发性视网膜母细胞瘤中。

方法

采用免疫印迹分析来确定神经激肽-1受体,使用库尔特计数器来确定活细胞数量;随后应用四氮唑化合物WST-8(一种比色法)来评估细胞活力。应用DAPI染色来评估凋亡特征性的染色质浓缩,并用免疫过氧化物酶法来证实原发性视网膜母细胞瘤眼中的神经激肽-1受体和P物质。

结果

在所研究的两种视网膜母细胞瘤细胞系中均存在神经激肽-1受体。在两种细胞系中均观察到三条相同的条带(约33、58和75 kDa的异构体)。此外,无论之前是否给予P物质,L-732,138均抑制了所研究的两种细胞系的生长。这种抑制呈剂量依赖性,WERI-Rb1的IC50值为60.47 microM,Y-79的IC50值为56.78 microM。此外,给予L-732,138或L-733,060后,在两种细胞系中均观察到凋亡。在原发性视网膜母细胞瘤的固定眼中,在肿瘤细胞中观察到高密度的神经激肽-1受体,而含有P物质的此类细胞数量极少。

结论

本研究表明,人视网膜母细胞瘤细胞系WERI-Rb-1和Y-79中存在相同异构体形式的神经激肽-1受体。L-732,138和L-733,060均可诱导这些细胞系凋亡,因此可作为抗肿瘤药物。原发性视网膜母细胞瘤标本显示神经激肽-1受体免疫标记。这些结果表明,神经激肽-1受体可能是视网膜母细胞瘤治疗的一个有前景的新靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验